These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19068983)

  • 1. [Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia].
    Mlika BR; El Aïdli S; Ben Brahim M; Badri T; Chouk S; Ben Jannet S; Marrrak H; Daghfous R; Mokhtar I; Fenniche S
    Med Trop (Mars); 2008 Oct; 68(5):499-501. PubMed ID: 19068983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.
    Mlika RB; Hamida MB; Hammami H; Jannet SB; Badri T; Fenniche S; Mokhtar I
    Dermatol Ther; 2012; 25(6):615-8. PubMed ID: 23210761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glucantime injection: benefit versus toxicity].
    Masmoudi A; Maalej N; Mseddi M; Souissi A; Turki H; Boudaya S; Bouassida S; Zahaf A
    Med Mal Infect; 2005 Jan; 35(1):42-5. PubMed ID: 15695033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis].
    Masmoudi A; Maalej N; Boudaya S; Turki H; Zahaf A
    Med Mal Infect; 2006 Apr; 36(4):226-8. PubMed ID: 16600554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
    Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
    Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I; Farajzadeh S; Rahnama Z; Fathabadi EA; Heshmatkhah A
    Int J Dermatol; 2012 Oct; 51(10):1221-5. PubMed ID: 22994669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.
    Rodrigues ML; Costa RS; Souza CS; Foss NT; Roselino AM
    Rev Inst Med Trop Sao Paulo; 1999; 41(1):33-7. PubMed ID: 10436668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
    Mohammadzadeh M; Behnaz F; Golshan Z
    J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
    Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
    J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report].
    Matoussi N; Ameur HB; Amor SB; Fitouri Z; Becher SB
    Med Mal Infect; 2007 Dec; 37 Suppl 3():S257-9. PubMed ID: 18054189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate.
    Neves DB; Caldas ED; Sampaio RN
    Trop Med Int Health; 2009 Dec; 14(12):1515-22. PubMed ID: 19954451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime.
    Sadeghian G; Ziaei H; Sadeghi M
    Ann Acad Med Singap; 2008 Nov; 37(11):916-8. PubMed ID: 19082196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glucantime reaction with fatal outcome following treatment of cutaneous leishmaniasis].
    Hajlaoui K; Zeglaoui F; Ezzine N; Kastalli S; Elfekih N; Fazaa B; Loueslati MH; Kamoun MR
    Ann Dermatol Venereol; 2008 Apr; 135(4):317-8. PubMed ID: 18420083
    [No Abstract]   [Full Text] [Related]  

  • 17. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
    Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis.
    Rajabi O; Layegh P; Hashemzadeh S; Khoddami M
    Dermatol Ther; 2016 Sep; 29(5):358-363. PubMed ID: 27073044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.
    Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F
    Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.
    Miranda-Verástegui C; Llanos-Cuentas A; Arévalo I; Ward BJ; Matlashewski G
    Clin Infect Dis; 2005 May; 40(10):1395-403. PubMed ID: 15844060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.